<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925011</url>
  </required_header>
  <id_info>
    <org_study_id>Roxadustat for pediatric CKD</org_study_id>
    <nct_id>NCT04925011</nct_id>
  </id_info>
  <brief_title>Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD</brief_title>
  <official_title>An Open-label, One-center Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mao Jianhua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Children's Hospital of Zhejiang University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-labeled, one-center study is designed to evaluate the efficacy and safety of&#xD;
      roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5 who&#xD;
      are receiving dialysis or not. The study will enroll patients between the ages of 2 to &lt;18&#xD;
      years. Approximately 30 patients will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the use of roxadustat for renal anemia in pediatric patients with&#xD;
      CKD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with mean Hb ≥ 11.0 g/dL</measure>
    <time_frame>weeks 16-24</time_frame>
    <description>After the use of roxadustat, the proportion of patients with mean Hb ≥ 11.0 g/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Hb</measure>
    <time_frame>weeks 16-24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anemia Associated With Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.</description>
    <arm_group_label>Roxadustat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Estimated glomerular filtration rate (Bedside Schwartz formula) of &lt; 60 ml/min/1.73 m2&#xD;
             (stage 3, 4 and 5 CKD) for dialysis or non-dialysis patients.&#xD;
&#xD;
          2. For ESA-naïve patients, mean of two most recent central laboratory Hb values during&#xD;
             the screening period obtained at least 2 days apart must be &lt; 11.0 g/dL. For patients&#xD;
             currently receiving stable ESA dosing who will discontinue ESA and convert to&#xD;
             roxadustat during study, mean of two most recent central laboratory Hb values during&#xD;
             the screening period obtained at least 2 days apart must be ≥ 9.0 g/dL and ≤ 12.5 g/dL&#xD;
&#xD;
          3. Ferritin &gt;50 ng/mL and transferrin saturation &gt;10%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled hypertension as judged by the principal investigator prior to screening.&#xD;
&#xD;
          2. Known hematologic disease related anemia (including PRCA)&#xD;
&#xD;
          3. Known malignancy within the past 5 years before screening.&#xD;
&#xD;
          4. History of severe anaphylaxis or known allergic to ingredient of roxadusta.&#xD;
&#xD;
          5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit&#xD;
             of normal (ULN) and total bilirubin (Tbili) ≤2x ULN(obtained from screening visit).&#xD;
&#xD;
          6. Serum folate and vitamin B12 &gt; LLN and cannot be corrected (obtained from screening&#xD;
             visit).&#xD;
&#xD;
          7. Any RBC transfusion during the past 4 weeks before screening.&#xD;
&#xD;
          8. Weight&lt;10kg&#xD;
&#xD;
          9. Any prior exposure to roxadustat or any other HIF-PH inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianhua Map, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianhua Mao, MD</last_name>
    <phone>086-571-86670015</phone>
    <email>maojh88@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>fei Liu</last_name>
    <email>alexdevin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao Jianhua</last_name>
      <phone>13616819071</phone>
      <email>maojh88@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Children's Hospital of Zhejiang University School of Medicine</investigator_affiliation>
    <investigator_full_name>Mao Jianhua</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

